Are epigenetic drugs for diabetes and obesity at our door step? Academic Article

abstract

• Recent interest in epigenetics has focused on small molecules aimed at modifying disease-specific gene expression, including diabetes and obesity. Several major classes of epigenetic modifier include drugs already in the marketplace as well as several in various stages of study. These classes include histone deacetylase inhibitors (HDACi), histone acetyltransferase inhibitors (HATi), protein arginine methyltransferase inhibitors (PRMTis), DNA methyltransferase inhibitors (DNMTis), histone demethylating inhibitors (HDMis), and sirtuin-activating compounds (STACs). In this review, we discuss drugs with epigenetic properties that have been identified as potential therapeutic agents in the treatment of diabetes and obesity, including those currently in clinical trials.

authors

• Bowman, John
• Choudhury, Mahua

published proceedings

• Drug Discov Today

altmetric score

• 11.6

author list (cited authors)

• Arguelles, A. O., Meruvu, S., Bowman, J. D., & Choudhury, M.

citation count

• 55

complete list of authors

• Arguelles, Andrix O||Meruvu, Sunitha||Bowman, John D||Choudhury, Mahua

publication date

• March 2016

publisher

• Elsevier  Publisher

published in

• Drug Discovery Today  Journal

keywords

• Animals
• Diabetes Mellitus
• Dna Modification Methylases
• Epigenesis, Genetic
• Histone Acetyltransferases
• Histone Deacetylase Inhibitors
• Histone Demethylases
• Humans
• Obesity
• Sirtuins

PubMed Central ID

• 26697737

Digital Object Identifier (DOI)

• 10.1016/j.drudis.2015.12.001

start page

• 499

end page

• 509

volume

• 21

issue

• 3

URL

• http://dx.doi.org/10.1016/j.drudis.2015.12.001